‘The situation has become appalling’: fake scientific papers push research credibility to crisis point
By Robin McKie,
The Guardian
| 02. 03. 2024
Tens of thousands of bogus research papers are being published in journals in an international scandal that is worsening every year, scientists have warned. Medical research is being compromised, drug development hindered and promising academic research jeopardised thanks to a global wave of sham science that is sweeping laboratories and universities.
Last year the annual number of papers retracted by research journals topped 10,000 for the first time. Most analysts believe the figure is only the tip of an iceberg of scientific fraud.
“The situation has become appalling,” said Professor Dorothy Bishop of Oxford University. “The level of publishing of fraudulent papers is creating serious problems for science. In many fields it is becoming difficult to build up a cumulative approach to a subject, because we lack a solid foundation of trustworthy findings. And it’s getting worse and worse.”
The startling rise in the publication of sham science papers has its roots in China, where young doctors and scientists seeking promotion were required to have published scientific papers. Shadow organisations – known as “paper mills” – began to supply fabricated...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...